Navigation Links
Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
Date:2/27/2008

outstanding at December 31, 2007.

Arena's 2007 Highlights

-- Initiated BLOSSOM and BLOOM-DM, the second and third Phase 3 pivotal

trials evaluating the efficacy and safety of Arena's lead drug

candidate, lorcaserin hydrochloride, or lorcaserin, for the treatment

of obesity. These one-year, double-blind, randomized and

placebo-controlled trials are expected to collectively enroll

approximately 3,750 overweight and obese patients. Consistent with

Arena's proposal, the US Food and Drug Administration, or FDA, has

allowed Arena to eliminate the requirement to perform

echocardiographic testing prior to enrolling patients in both BLOSSOM

and BLOOM-DM. This is different from the design of BLOOM, the initial

lorcaserin pivotal study, in which echocardiography was used to screen

for patients with FDA-defined valvulopathy, and certain other

echocardiographic abnormalities, and exclude those patients from

enrolling in the trial.

-- Completed a public offering of 11.0 million shares of common stock at

$9.91 per share, resulting in net proceeds to Arena of approximately

$103.2 million.

-- Announced positive preliminary results from Arena's Phase 2a clinical

trial of APD125 in patients with chronic insomnia. In this Phase 2a

clinical trial, APD125 significantly improved endpoints measuring

improvements in sleep maintenance with no observations of next day

cognitive impairment.

-- Reported that an independent Echocardiographic Safety Monitoring Board

found no reason to stop the ongoing pivotal Phase 3 lorcaserin BLOOM

trial following a planned review of unblinded echocardiograms

performed after patients completed six months of dosing in the trial.

The review confirmed that differences, if any, in the rates of
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
11. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2009)... Inc. (Nasdaq: ENMD ), today announced the ... sales of Thalomid® during the third quarter compared ... In addition, the Company anticipates a decrease in ... The difference in estimated and actual revenues ... the fourth quarter financial results. ,, (Logo: ...
(Date:12/11/2009)... miRagen Therapeutics, Inc., a biopharmaceutical company focused ... therapeutics for cardiovascular and muscle disease, today announced ... plays a crucial role in the progression of ... and in neuromuscular synaptic regeneration in mice. ... of the journal Science , reveal miR-206 ...
(Date:12/11/2009)... have observed the "hot electron" effect in a solar ... elusive charges using ultra-thin solar cells, opening a potential ... in the current online edition of Applied Physics ... cells, it generates free electrons in a range of ... the electrons must reach the bottom of the conduction ...
(Date:12/11/2009)... Algeta ASA (OSE: ALGETA), the,cancer therapeutics company, ... the,US, the Tulane Cancer Center, New Orleans, ... clinical study of Alpharadin in men with,castration-resistant ... has metastasized to the skeleton. , ... SYMptomatic Prostate CAncer) study is a,double-blind, randomized, ...
Breaking Biology Technology:EntreMed Reports Receipt of Third Quarter Royalty Payment 2miRagen announces discovery of key microRNA implicated in Lou Gehrig's disease 2Elusive 'hot' electrons captured in ultra-thin solar cells 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 3Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 4
... increased 40.8% to $11.6 million ... Net Income increased 118.8% to $2.5 ... China Medicine,Corporation (OTC Bulletin Board: CHME) ("China Medicine" ... prescription and over-the-counter,pharmaceuticals, traditional Chinese medicines ("TCM"), nutritional ...
... Tate & Lyle Bio Products today announced that its breakthrough ... a natural ingredient by ECOCERT®, one of the leading international ... ... Loudon, TN August 13, 2008 –- http://www.duponttateandlyle.com/ [DuPont ...
... from the Defense Threat Reduction Agency Will Fund the, Advanced Development ... ... Countermeasure -, CHICAGO, Aug. 13 Advanced Life Sciences,Holdings, ... Agency (DTRA) of the U.S. Department of Defense has awarded the,Company ...
Other Biology Technology:China Medicine Announces Strong Second Quarter 2008 Results 2China Medicine Announces Strong Second Quarter 2008 Results 3China Medicine Announces Strong Second Quarter 2008 Results 4China Medicine Announces Strong Second Quarter 2008 Results 5China Medicine Announces Strong Second Quarter 2008 Results 6China Medicine Announces Strong Second Quarter 2008 Results 7China Medicine Announces Strong Second Quarter 2008 Results 8China Medicine Announces Strong Second Quarter 2008 Results 9China Medicine Announces Strong Second Quarter 2008 Results 10China Medicine Announces Strong Second Quarter 2008 Results 11Zemea Propanediol Approved as a Natural Ingredient by ECOCERT 2Zemea Propanediol Approved as a Natural Ingredient by ECOCERT 3Advanced Life Sciences Awarded U.S. Department of Defense Biodefense Contract Valued at up to $3.8 Million 2Advanced Life Sciences Awarded U.S. Department of Defense Biodefense Contract Valued at up to $3.8 Million 3Advanced Life Sciences Awarded U.S. Department of Defense Biodefense Contract Valued at up to $3.8 Million 4
(Date:12/14/2009)... be transmitted by sneezing, touching, or for Tasmanian ... habit that may have driven the dinosaurs to extinction ... Upcroft, a member of f1000 Biology, highlights the ,paleobiological ... PLoS One. This led them to deduce that a ... bones seen in many tyrannosaurid fossils. , The parasite,s ...
(Date:12/14/2009)... defining feature of humans. That,s until examples of tool use ... array of other mammals. Now, a report in the December ... publication, adds an octopus to the growing list of tool ... trick that the researchers call stilt walking. In it, the ... makes its eight arms rigid, and raises the whole assembly ...
(Date:12/13/2009)... about how a popular class of drugs used ... previously hidden components of chemical communication in the ... the illness, people with schizophrenia also struggle to ... order, difficulties that interfere with their ability to ... Schroeder, a student in the medical scientist training ...
Breaking Biology News(10 mins):Tool use in an invertebrate: The coconut-carrying octopus 2New biosensors reveal workings of anti-psychotic drugs in the living brain 2NYU Langone Medical Center awarded NIH grants totaling 241 560 000 8981 1NYU Langone Medical Center awarded NIH grants totaling 241 560 000 8981 2NYU Langone Medical Center awarded NIH grants totaling 241 560 000 8981 3Give an Hour 28TM 29s Volunteer Mental Health Professionals Provide More Than 241 4 Million in Services to Iraq and Afghanistan Veterans Families a 49927 1Give an Hour 28TM 29s Volunteer Mental Health Professionals Provide More Than 241 4 Million in Services to Iraq and Afghanistan Veterans Families a 49927 2Give an Hour 28TM 29s Volunteer Mental Health Professionals Provide More Than 241 4 Million in Services to Iraq and Afghanistan Veterans Families a 49927 3PHT Names VP to Lead Sales of A Claim Payment Solution for Doctors Hospitals 49924 1PHT Names VP to Lead Sales of A Claim Payment Solution for Doctors Hospitals 49924 2
... new antimicrobial approach can kill bacteria in laboratory experiments ... a key bacterial nutrient, according to research led by ... at the UW, the University of Iowa, and the ... 2 issue of the Journal of Clinical Investigation. ...
... bacterial composition of the oral cavity even in low doses. ... needed to counteract the production of acid between the teeth, ... defend at Umeå University in Sweden on February 23. , ... of the sugar xylose, or wood sugar. Xylitol occurs ...
... light are providing insight into the complexities of the sense ... how the human brain works. , Investigators at Duke University ... a strain of mice whose olfactory brain cells "fire" when ... cells a gene naturally present in green algae that "turns ...
Other Biology News:Trojan horse strategy defeats drug-resistant bacteria 2Xylitol reduces risk of cavities 2Common algae helps illustrate mammalian brain electrical circuitry 2Common algae helps illustrate mammalian brain electrical circuitry 3
Rabbit anti-T-box 6...
TNF-R2 (L-20)...
Assay Kit formatted for flow cytometric detection of levels of phosphorylated histone H2A.X....
... SizeSep 400 Spun Columns, 10. *SizeSep ... cDNAs > 400 base pairs in length. ... Sepharose CL-4B and pre-equilibrated in distilled water containing ... smaller than ~ 400 base pairs. ...
Biology Products: